Browse studies

Find your next paid study

349 recruiting studies matching your filters

A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Pha…

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors

A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with doc…

Advanced Solid Tumors

Estimated

~$10 – $8,750

Vividion Therapeutics, Inc.NCT05954312

Phase 1

A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors

Advanced Solid Tumors

Estimated

~$10 – $8,750

Jacobio Pharmaceuticals Co., Ltd.NCT06973564

Phase 1

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors With Bone Metastases

This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally ad…

Carcinoma, Non-Small-Cell Lung CancerBone Metastases From Solid Tumors

Estimated

~$10 – $8,750

Kiromic BioPharma Inc.NCT06069570

Phase 1

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Solid TumorsER+ Breast CancerTriple Negative Breast Cancer, TNBC+2 more

Estimated

~$10 – $8,750

Jacobio Pharmaceuticals Co., Ltd.NCT05490472

Phase 1

A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast canc…

Advanced Solid Tumors

Estimated

~$10 – $8,750

Eikon TherapeuticsNCT06907043

Phase 1

An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in on…

Solid Tumors, Adult

Estimated

~$10 – $8,750

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT06504368

Phase 1

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and …

Intracranial GliomaMetastatic Brain TumorBreast Cancer+2 more

Estimated

~$10 – $7,500

Barbara Ann Karmanos Cancer InstituteNCT05556473

Phase 1

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combinati…

Advanced Solid Tumors

Estimated

~$10 – $8,750

AskGene Pharma, Inc.NCT05867420

Phase 1

Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2- ICG in a Phase 1 Clinical Trial

Participants in this research study are people who are likely to have, or have been diagnosed with a brain tumor, for which surgical removal (or "resection") i…

Malignant Brain TumorsGlioma

Estimated

~$10 – $7,500

Tiffany HodgesNCT07438860

Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of …

Solid TumorsHematologic Malignancies

Estimated

~$10 – $750

Mayo ClinicNCT02457962

Phase 2

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which t…

Breast NeoplasmsBreast CancerBreast Tumors+8 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT01042379